Literature DB >> 20503401

Inflammatory breast cancer in Tunisia: epidemiological and clinical trends.

Hamouda Boussen1, Hatem Bouzaiene, Jamel Ben Hassouna, Tarek Dhiab, Fathi Khomsi, Farouk Benna, Amor Gamoudi, Nejib Mourali, Monia Hechiche, Khaled Rahal, Paul H Levine.   

Abstract

Inflammatory breast cancer (IBC) is characterized by a peculiar geographic distribution in incidence, being described as more common in Tunisia and the region of North Africa. The authors performed a systematic review of published literature on rapidly progressing breast cancer and IBC in Tunisia and analyzed the evolution in epidemiology, clinical presentation, treatment, and therapeutic results. They collected, analyzed, and compared all the indexed Tunisian articles about rapidly progressing breast cancer and IBC since the 1970s opening of the Institut Salah Azaiz Institute in Tunis. In the 1970s, rapidly progressing breast cancer diagnosis was based on the Poussée Evolutive classification (1-3). Since the 1990s, IBC diagnosis has been based on the American Joint Committee on Cancer Poussée Evolutive 3/T4d staging. The authors compared the historical data to the most recent publications in terms of epidemiology, clinical features, treatment, and therapeutic results. The most important historical report of rapidly progressing breast cancer concerned 340 patients, representing 58.5% of a cohort of 581 breast cancer patients collected from 1969 to 1974, including 320 (55.2%) with inflammatory signs, 37(6.5%) with Poussée Evolutive 2, and 283 (48.7%) with Poussée Evolutive 3. Subsequent papers have documented a steady decrease in incidence to the current 5% to 7% T4d/IBC. Since the 1970s, Poussée Evolutive in premenopausal woman has increased from 52.5% to 75%; rural predominance has persisted. The 5-year overall survival reached 28% by the year 2000. The authors' analysis demonstrated a trend of decreasing incidence of IBC diagnoses from 50% to presently <10%, probably related to a combination of factors, including the use of more stringent criteria (Poussée Evolutive 3/T4d) for IBC diagnosis and an improvement in the socioeconomic level of Tunisia. Copyright 2010 American Cancer Society.

Entities:  

Mesh:

Year:  2010        PMID: 20503401     DOI: 10.1002/cncr.25175

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  20 in total

Review 1.  Inflammatory breast cancer clusters: A hypothesis.

Authors:  Paul H Levine; Salman Hashmi; Ashley A Minaei; Carmela Veneroso
Journal:  World J Clin Oncol       Date:  2014-08-10

2.  Molecular and epidemiological characteristics of inflammatory breast cancer in Algerian patients.

Authors:  Nabila Chaher; Hugo Arias-Pulido; Nadija Terki; Clifford Qualls; Kamel Bouzid; Claire Verschraegen; Anne Marie Wallace; Melanie Royce
Journal:  Breast Cancer Res Treat       Date:  2011-03-01       Impact factor: 4.872

3.  What can we learn from the age- and race/ethnicity- specific rates of inflammatory breast carcinoma?

Authors:  Dora Il'yasova; Sharareh Siamakpour-Reihani; Igor Akushevich; Lucy Akushevich; Neil Spector; Joellen Schildkraut
Journal:  Breast Cancer Res Treat       Date:  2011-08-18       Impact factor: 4.872

4.  Association of inflammatory and noninflammatory breast cancer with socioeconomic characteristics in the Surveillance, Epidemiology, and End Results database, 2000-2007.

Authors:  Jennifer A Schlichting; Amr S Soliman; Catherine Schairer; Mousumi Banerjee; Laura S Rozek; David Schottenfeld; Joe B Harford; Sofia D Merajver
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-10-25       Impact factor: 4.254

5.  Relapse profile of early breast cancer according to immunohistochemical subtypes: guidance for patient's follow up?

Authors:  Nesrine Mejri; H Boussen; S Labidi; F Benna; M Afrit; K Rahal
Journal:  Ther Adv Med Oncol       Date:  2015-05       Impact factor: 8.168

6.  A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer.

Authors:  Massimo Cristofanilli; Stephen R D Johnston; Alexey Manikhas; Henry L Gomez; Oleg Gladkov; Zhimin Shao; Sufia Safina; Kimberly L Blackwell; Ricardo H Alvarez; Stephen D Rubin; Sulabha Ranganathan; Suman Redhu; Maureen E Trudeau
Journal:  Breast Cancer Res Treat       Date:  2012-12-13       Impact factor: 4.872

7.  miRNAs in Sera of Tunisian patients discriminate between inflammatory breast cancer and non-inflammatory breast cancer.

Authors:  Khouloud Hamdi; David Goerlitz; Neila Stambouli; Mohammed Islam; Olfa Baroudi; Bilel Neili; Farhat Benayed; Simon Chivi; Christopher Loffredo; Irene A Jillson; Amel Benammar Elgaaied; Jan K Blancato; Raja Marrakchi
Journal:  Springerplus       Date:  2014-10-28

8.  Assessment of diagnosis of inflammatory breast cancer cases at two cancer centers in Egypt and Tunisia.

Authors:  Catherine Schairer; Amr S Soliman; Sherif Omar; Hussein Khaled; Saad Eissa; Farhat Ben Ayed; Samir Khalafallah; Wided Ben Ayoub; Elizabeth D Kantor; Sofia Merajver; Sandra M Swain; Mitchell Gail; Linda Morris Brown
Journal:  Cancer Med       Date:  2013-01-24       Impact factor: 4.452

9.  Considerations in setting up and conducting epidemiologic studies of cancer in middle- and low-income countries: the experience of a case-control study of inflammatory breast cancer in North Africa in the past 10 years.

Authors:  Amr S Soliman; Catherine Schairer
Journal:  Cancer Med       Date:  2012-10-11       Impact factor: 4.452

10.  Characterizing inflammatory breast cancer among Arab Americans in the California, Detroit and New Jersey Surveillance, Epidemiology and End Results (SEER) registries (1988-2008).

Authors:  Kelly A Hirko; Amr S Soliman; Mousumi Banerjee; Julie Ruterbusch; Joe B Harford; Robert M Chamberlain; John J Graff; Sofia D Merajver; Kendra Schwartz
Journal:  Springerplus       Date:  2013-01-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.